Cholera Toxin Enhances Vaccine-Induced Protection against Mycobacterium Tuberculosis Challenge in Mice

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Griffiths, Kristin L ^a   Stylianou, Elena ^a   Poyntz, Hazel C ^a   Betts, Gareth J ^a   Fletcher, Helen A ^a   McShane, Helen ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CD4 ANTIGEN; CHOLERA TOXIN; GAMMA INTERFERON; INTERLEUKIN 17;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL LOAD; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MODEL; DRUG DOSAGE FORM COMPARISON; DRUG POTENTIATION; DRUG SAFETY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROVOCATION; TREATMENT OUTCOME; TUBERCULOSIS; ANALYSIS OF VARIANCE; ANIMAL; IMMUNOLOGY; NONPARAMETRIC TEST;

ANALYSIS OF VARIANCE; ANIMALS; BCG VACCINE; CHOLERA TOXIN; INTERLEUKIN-17; MICE; MYCOBACTERIUM TUBERCULOSIS; STATISTICS, NONPARAMETRIC; TUBERCULOSIS;

EID: 84886010092     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078312     Document Type: Article

References (33)

1. WHO (2012) Tuberculosis.
2. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, et al. (1994) Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271: 698-702.
3. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, et al. (2007) IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8: 369-377.
4. Gopal R, Lin Y, Obermajer N, Slight S, Nuthalapati N, et al. (2012) IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination. Eur J Immunol 42: 364-373.
5. Vordermeier HM, Villarreal-Ramos B, Cockle PJ, McAulay M, Rhodes SG, et al. (2009) Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect Immun 77: 3364-3373.
6. Streicher EM, Muller B, Chihota V, Mlambo C, Tait M, et al. (2012) Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa. Infect Genet Evol 12: 686-694.
7. Cowan J, Pandey S, Filion LG, Angel JB, Kumar A, et al. (2012) Comparison of interferon-gamma-, interleukin (IL)-17- and IL-22-expressing CD4 T cells, IL-22-expressing granulocytes and proinflammatory cytokines during latent and active tuberculosis infection. Clin Exp Immunol 167: 317-329.
8. Jurado JO, Pasquinelli V, Alvarez IB, Pena D, Rovetta AI, et al. (2012) IL-17 and IFN-gamma expression in lymphocytes from patients with active tuberculosis correlates with the severity of the disease. J Leukoc Biol 91: 991-1002.
9. Qiao D, Yang B, Li L, Ma J, Zhang X, et al. (2011) ESAT-6- and CFP-10-specific Th1, Th22 and Th17 cells in tuberculous pleurisy may contribute to the local immune response against Mycobacterium tuberculosis infection. Scand J Immunol.
10. Scriba TJ, Kalsdorf B, Abrahams DA, Isaacs F, Hofmeister J, et al. (2008) Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response. J Immunol 180: 1962-1970.
11. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, et al. (2004) Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10: 1240-1244.
12. Minassian AM, Rowland R, Beveridge NE, Poulton ID, Satti I, et al. (2011) A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults. BMJ Open 1: e000223.
13. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, et al. (2013) Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381: 1021-1028.
14. De Cassan S, Pathan A, Sander C, Minassian A, Hill AV, et al. (2010) Investigating the induction of vaccine induced Th17 and regulatory T cells in healthy, BCG immunised adults vaccinated with a new tuberculosis vaccine, MVA85A. Clin Vaccine Immunol 17: 1066-1073.
15. Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, et al. (2010) Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol 40: 279-290.
16. Griffiths KL, Pathan AA, Minassian AM, Sander CR, Beveridge NE, et al. (2011) Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A. PLoS One 6: e23463.
17. Cubillos S, Norgauer J, Lehmann K, (2010) Toxins-useful biochemical tools for leukocyte research. Toxins (Basel) 2: 428-452.
18. la Sala A, He J, Laricchia-Robbio L, Gorini S, Iwasaki A, et al. (2009) Cholera toxin inhibits IL-12 production and CD8alpha+ dendritic cell differentiation by cAMP-mediated inhibition of IRF8 function. J Exp Med 206: 1227-1235.
19. Datta SK, Sabet M, Nguyen KP, Valdez PA, Gonzalez-Navajas JM, et al. (2010) Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax. Proc Natl Acad Sci U S A.
20. Lee JB, Jang JE, Song MK, Chang J, (2009) Intranasal delivery of cholera toxin induces th17-dominated T-cell response to bystander antigens. PLoS One 4: e5190.
21. Parra M, Derrick SC, Yang A, Tian J, Kolibab K, et al. (2011) Malaria infections do not compromise vaccine-induced immunity against tuberculosis in mice. PLoS One 6: e28164.
22. Deroulers C, Ameisen D, Badoual M, Gerin C, Granier A, et al. (2013) Analyzing huge pathology images with open source software. Diagn Pathol 8: 92.
23. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, et al. (2003) Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 171: 1602-1609.
24. Lefford MJ, (1977) Induction and expression of immunity after BCG immunization. Infection and immunity 18: 646-653.
25. Lyadova IV, Vordermeier HM, Eruslanov EB, Khaidukov SV, Apt AS, et al. (2001) Intranasal BCG vaccination protects BALB/c mice against virulent Mycobacterium bovis and accelerates production of IFN-gamma in their lungs. Clinical and experimental immunology 126: 274-279.
26. Chen L, Wang J, Zganiacz A, Xing Z, (2004) Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Infection and immunity 72: 238-246.
27. Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, et al. (2008) Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 172: 146-155.
28. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, et al. (2008) Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. The Journal of investigative dermatology 128: 1207-1211.
29. Shen H, Goodall JC, Hill Gaston JS, (2009) Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 60: 1647-1656.
30. Khader SA, Guglani L, Rangel-Moreno J, Gopal R, Junecko BA, et al. (2011) IL-23 is required for long-term control of Mycobacterium tuberculosis and B cell follicle formation in the infected lung. J Immunol 187: 5402-5407.
31. Santos AA, Jr., Rodrigues-Junior V, Zanin RF, Borges TJ, Bonorino C, et al. (2013) Implication of purinergic P2X7 receptor in M. tuberculosis infection and host interaction mechanisms: A mouse model study. Immunobiology.
32. Lister MF, Sharkey J, Sawatzky DA, Hodgkiss JP, Davidson DJ, et al. (2007) The role of the purinergic P2X7 receptor in inflammation. J Inflamm (Lond) 4: 5.
33. Yu J, Sheung N, Soliman EM, Spirli C, Dranoff JA, (2009) Transcriptional regulation of IL-6 in bile duct epithelia by extracellular ATP. Am J Physiol Gastrointest Liver Physiol 296: G563-571.